There are a lot of ASX shares to choose from on the Australian share market. But which ones could be buys today?
To narrow things down, let's take a look at three shares that Morgans has been running the rule over this week. Does it rate them as buys, holds, or sells? Let's find out:
Image source: Getty Images
Credit Corp Group Ltd (ASX: CCP)
Morgans notes that this debt collector released a half-year result that was short of expectations. However, due to significant share price weakness, the broker thinks a buying opportunity has opened up. It is recommending Credit Corp shares as a buy with a trimmed price target of $19.35. It said:
CCP's 1H26 NPAT of ~A$44m (flat on the pcp) was ~10% under consensus/MorgE. Whilst guidance was reiterated, the compositional mix shift towards AU debt purchases for FY26 (revised upwards) and the lowering of US purchasing guidance (noting some increased competitive pricing) saw the stock close ~17% lower.
Operational efficiency/productivity has improved, however delivering on US divisional growth is key to our long-term investment thesis and a key catalyst. At ~7x FY27 PE (MorgE) the valuation appears undemanding. BUY maintained.
PLS Group Ltd (ASX: PLS)
This lithium miner's shares could be fully valued now according to Morgans. In response to its strong quarterly update, the broker has upgraded PLS shares to a hold rating with a $4.60 price target. It explains:
Strong 2Q26 with a material spodumene sales and revenue beat vs MorgansF and consensus expectations. Cash balance +12% qoq with total liquidity of ~A$1.6bn leaving significant flexibility to fund growth and consider shareholder returns.
Management is assessing the potential restart of the 200ktpa Ngungaju plant and other growth options in P2000 and Colina. Upgrade to HOLD (previously TRIM) on recent share price weakness with an unchanged A$4.60ps target price.
ResMed Inc. (ASX: RMD)
Morgans was impressed with the sleep disorder treatment company's second-quarter update, which came in ahead of expectations.
The broker has responded to the result by upgrading ResMed shares to a buy rating with a $47.73 price target. It said:
2Q beat across the board, with double-digit revenue and earnings growth, further gross margin expansion and solid cash generation. Sleep and respiratory sales were strong in both regions, with above-market growth in the Americas and ROW returning to market growth, while SaaS beat expectations, but remained subdued by residential care headwinds.
Operating leverage improved again, with gross margin gains from manufacturing and logistics efficiencies, and FY26 guidance tightened to 62-63% (from 61-63%), reinforcing confidence in ongoing margin progression. We adjust FY26-28 forecasts modestly and move to BUY with a A$47.73 target price, viewing recent share weakness unjustified given sound fundamentals.
